血漿療法の市場規模、シェア、成長分析：タイプ別、供給源別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

血漿療法の世界市場規模は、2023年に3億1,000万米ドルと評価され、2024年の3億5,433万米ドルから2032年には10億3,223万米ドルに拡大し、予測期間（2025年～2032年）のCAGRは14.3％で成長する見通しです。

血漿療法市場は、男性型脱毛症やスポーツ関連傷害の増加により、成長が見込まれています。血漿は抗体濃度が高いため、その治療用途は免疫伝達を提供し、特に整形外科、皮膚科、歯科で有益です。様々な治療分野で多血小板血漿（PRP）の採用が増加していることも、大きな成長触媒となっています。しかし、償還の枠組みの欠如、血漿療法に関連するさまざまなコスト、糖尿病患者や腎不全患者における限定的な有効性といった課題が、市場拡大の妨げになる可能性があります。さらに、関節炎患者の急増が成長を減速させる可能性もあります。全体として、増加する患者の需要と新たな治療アプリケーションの融合は、この分野の利害関係者に大きな将来機会をもたらします。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ分析

血漿療法市場規模：タイプ別

• 市場概要
• 純粋PRP
• 白血球を多く含むPRP
• 純粋血小板を多く含むフィブリン
• 白血球を多く含むフィブリン

血漿療法市場規模：供給源別

• 市場概要
• 自家
• 同種

血漿療法市場規模：用途別

• 市場概要
• 整形外科
  • 関節炎
  • 慢性腱炎
  • 骨の修復と再生
• 皮膚科
  • 男性型脱毛症
  • 形成外科
• 心筋損傷
• 歯科
• 神経損傷
• その他

血漿療法市場規模：エンドユーザー別

• 市場概要
• 病院・クリニック
• 調査機関

血漿療法市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• CSL Behring（Australia）
• Grifols S.A.（Spain）
• Kedrion S.p.A.（Italy）
• Octapharma AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Zimmer Biomet（US）
• Baxter International Inc.（US）
• China Biologic Products Holdings, Inc.（China）
• GC Pharma（South Korea）
• Green Cross Corp.（South Korea）
• Japan Blood Products Organization（Japan）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• China National Biotec Group Co., Ltd.（CNBG）（China）
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.（China）
• Jiangxi Boya Bio-Pharmaceutical Co., Ltd.（China）
• Bio Products Laboratory Ltd.（BPL）（UK）
• BioLife Plasma Services（US）
• Canadian Plasma Resources（Canada）

結論と推奨事項

Global Plasma Therapy Market size was valued at USD 310.0 million in 2023 and is poised to grow from USD 354.33 million in 2024 to USD 1032.23 million by 2032, growing at a CAGR of 14.3% during the forecast period (2025-2032).

The market for plasma therapy is poised for growth, driven by the increasing incidence of androgenic alopecia and sports-related injuries. With plasma's high antibody concentration, its therapeutic application offers immunity transfer, particularly beneficial in orthopaedics, dermatology, and dentistry. The rising adoption of platelet-rich plasma (PRP) across various therapeutic areas is also a significant growth catalyst. However, challenges such as the lack of reimbursement frameworks, varied costs associated with plasma therapy, and limited efficacy in diabetic and kidney-compromised patients may hinder market expansion. Additionally, the surge in arthritis cases could moderate growth. Overall, the convergence of increasing patient demand and emerging treatment applications presents substantial future opportunities for stakeholders in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Therapy Market Segmental Analysis

Global Plasma Therapy Market is segmented by Type, Source, Application, End User and region. Based on Type, the market is segmented into Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin. Based on Source, the market is segmented into Autologous and Allogenic. Based on Application, the market is segmented into Orthopedic, Dermatology, Cardiac Muscle Injury, Dental, Nerve Injury and Others. Based on End User, the market is segmented into Hospitals & Clinics and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Plasma Therapy Market

The Global Plasma Therapy market is experiencing significant growth due to several driving factors. A notable increase in the use of platelet-rich plasma (PRP) is attributed to a surge in sports injuries, along with a rising demand for cosmetic procedures, as more individuals engage in athletic activities. Additionally, the expanded application of PRP in research is further propelling the sector forward. As awareness of the benefits of plasma therapy continues to grow, fueled by its effectiveness in healing and rejuvenation, the market is well-positioned for continued expansion, attracting both medical professionals and patients alike.

Restraints in the Global Plasma Therapy Market

The Global Plasma Therapy market faces significant restraints primarily due to the high costs associated with the treatment. The expenses involved in extracting plasma from blood and the subsequent storage requirements pose a challenge to market growth. In both developing and underdeveloped regions, these costs have greatly limited the accessibility and utilization of plasma therapy. As a result, the average individual often finds the treatment financially out of reach, which serves as a major barrier to market expansion. Consequently, the high financial burden associated with plasma therapy remains one of the primary factors hindering its wider adoption and development.

Market Trends of the Global Plasma Therapy Market

The global plasma therapy market is poised for significant growth driven by an increasing prevalence of androgenic alopecia and orthopedic disorders. As healthcare advancements expand treatment options, consumers are now empowered to select therapies aligned with their financial capabilities, thus enhancing market accessibility. Nevertheless, challenges persist, notably the limited application of platelet-rich plasma (PRP) in patients with diabetes and kidney issues, which may hinder market expansion. Additionally, the rise of innovative healthcare technologies is improving treatment efficacy, particularly for rare diseases, fostering increased interest in plasma therapies. Overall, these trends indicate a dynamic future landscape for the plasma therapy market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Plasma Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Pure PRP
• Leukocyte-Rich PRP
• Pure Platelet-Rich Fibrin
• Leukocyte-Rich Fibrin

Global Plasma Therapy Market Size by Source & CAGR (2025-2032)

• Market Overview
• Autologous
• Allogenic

Global Plasma Therapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Orthopedic
  • Arthritis
  • Chronic Tendinitis
  • Bone Repair & Regeneration
• Dermatology
  • Androgenic Alopecia
  • Plastic Surgery
• Cardiac Muscle Injury
• Dental
• Nerve Injury
• Others

Global Plasma Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Research Institutes

Global Plasma Therapy Market Size & CAGR (2025-2032)

• North America (Type, Source, Application, End User)
  • US
  • Canada
• Europe (Type, Source, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Source, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Source, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Source, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corp. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Blood Products Organization (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China National Biotec Group Co., Ltd. (CNBG) (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (BPL) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioLife Plasma Services (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canadian Plasma Resources (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations